Table 1.
Patient Characteristics
| Patient No. | Age (years) | Sex | Diagnosis and Stage | Prior Treatment |
|||
|---|---|---|---|---|---|---|---|
| Chemotherapy | Surgery | XRT | Other and/or Investigational Agents | ||||
| 1 | 21.2 | Female | OS, M | (1) MAPIE; (2) Ifos, VP16, HDMTX | LS | Y | (1) Bevacizumab; (2) sunitinib |
| 2 | 17.4 | Female | OS, L | (1) MAP; (2) Ifos | LS; M (3)* | N | (1) L-MTP-PE |
| 3 | 14.0 | Female | OS, M | (1) MAP; (2) Ifos, VP16, HDMTX | LS; M (5) | Y | (1) GCB; (2) L-MTP-PE, oral CPM; (3) sunitinib |
| 4 | 17.1 | Male | OS, L | (1) MAPIE | LS; M (4) | Y | (1) SCH717454; (2) L-MTP-PE; (3) sunitinib; (4) GCB, docetaxel, bevacizumab; (5) Doxo |
| 5 | 7.7 | Female | OS, M | (1) MAP; (2) Ifos, Carbo, VP16 (3) HD Ifos, HDMTX; (4) HDMTX | LS; M (3) | N | (1) L-MTP-PE, GCB; (2) L-MTP-PE, oral CPM; (3) denosumab, Doxo |
| 6 | 25.3 | Female | OS, L | (1) MAP; (2) Doxo, Ifos (3) HDMTX; (4) Ifos | Primary en bloc; M (1) | N | (1) L-MTP-PE, docetaxel; (2) GCB, bevacizumab, L-MTP-PE |
| 7 | 29.6 | Male | OS, L | (1) MAPIE | LS; M (3) | N | (1) L-MTP-PE; (2) L-MTP-PE, GCB |
| 8 | 15.4 | Female | OS, L | (1) MAP; (2) HD Ifos; (3) HDMTX, Cis; (4) oral CPM | Amp for quarter; M (4) | Y | (1) GCB; (2) Doxo, bevacizumab; (3) L-MTP-PE; (4) sorafenib |
| 9 | 21.1 | Female | OS, M | (1) MAP; (2) HD Ifos | LS; M (2) | Y | (1) Doxo; (2) L-MTP-PE |
| 10 | 14.0 | Female | PNET, L | (1) VDCIE; (2) Carbo, VP16, Mel + auto; (3) metronomic VCR; (4) TMZ, irinotecan | Rt kidney; M (1) | Y | (1) Sorafenib |
| 11 | 16.6 | Male | OS, L | (1) MAP; (2) Ifos, VP16 | LS; M (3) | N | (1) L-MTP-PE; (2) sunitinib; (3) Doxo |
| 12 | 11.3 | Male | DSCRT, L | (1) VDC × 2; (2) topotecan, CPM (3) TMZ, irinotecan; (4) vinorelbine, CPM | Primary en bloc; Hep emb | Y | (1) Sorafenib; (2) PEG-IFN |
| 13 | 20.6 | Male | OS, M | (1) MAPIE; (2) TMZ | LS; M (4) | Y | (1) L-MTP-PE; (2) bevacizumab, GCB, docetaxel; (3) sorafenib |
| 14 | 21.8 | Female | OS, L | (1) Intra-arterial Cis, Doxo, HDMTX, Ifos; (2) intrapleural Cis × 2; (3) HDMTX | LS; M (3) | N | (1) L-MTP-PE, oral CPM (2) Doxo, bevacizumab, HDMTX |
| 15 | 11.0 | Male | OS, M | (1) MAP | Amp; M (6) | Y | (1) L-MTP-PE; (2) GCB; (3) Doxo, bevacizumab; (4) sorafenib; (5) pazopanib, lapatinib |
| 16 | 19.3 | Male | OS, L | (1) Doxo, intra-arterial Cis, HDMTX (2) HD Ifos; (3) oral CPM; (4) Doxo, Ifos | LS; M (2) | N | (1) L-MTP-PE; (2) SCH717454 (IGF-1R MAb); (3) IFN; (4) sunitinib |
| 17 | 16.8 | Male | ES, M | (1) VDCIE; (2) VCR, TMZ, irinotecan; (3) vinoralbine, CPM | M (1) | Y | (1) Temsirolimus, IMC-A12; (2) Doxo; (3) vorinostat, pazopanib; (4) pazopanib, lapatinib |
| 18 | 14.5 | Female | OS, L | (1) MAPIE | LS; M (3) | N | None |
| 19 | 16.5 | Male | OS, M | (1) MAP; (2) HD Ifos, VP16 × 2 | LS; M (5) | Y | (1) Imetelstat |
Abbreviations: Amp, amputation; auto, autologous transplantation; Carbo, carboplatin; Cis, cisplatin; CPM, cyclophosphamide; Doxo, doxorubicin; DSRCT, desmoplastic small round cell tumor; ES, Ewing sarcoma; GCB, gemcitabine; HD, high dose; HDMTX, high-dose methotrexate; Hep emb, hepatic embolization; IFN, interferon; Ifos, ifosfamide; IGF-1R, insulin-like growth factor 1 receptor; L, localized; L-MTP-PE, liposome-encapsulated muramyl tripeptide phosphatidylethanolamine; LS, limb salvage; M, metastatic; M, metastasectomy; MAP, methotrexate, doxorubicin, and cisplatin; MAPIE, methotrexate, doxorubicin, cisplatin, ifosfamide, and etoposide; Mel, melphalan; N, no; OS, osteosarcoma; PEG-IFN, pegylated interferon; PNET, primitive neuroectodermal tumor; Rt, right; TMZ, temozolomide; VCR, vincristine; VDC, vincristine, doxorubicin, and cyclophosphamide; VDCIE, vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide; VP16, etoposide; XRT, radiation therapy; Y, yes.
No. of procedures.